Rintega rindopepimut regulatory update

FDA granted breakthrough therapy designation to Rintega rindopepimut from Celldex to treat EGFRvIII-positive glioblastoma multiforme (GBM) in adults. The vaccine targeting EGFR variant III ( EGFRvIII...